A method, system and storage medium for detecting and evaluating leg thrombosis

Abstract

The present invention belongs to the field of medical detection and intelligent diagnosis and treatment technology, and specifically relates to a leg thrombosis detection and evaluation method, system and storage medium. The system integrates a main control device and a blood flow velocity detection device, a vascular ultrasound detection device, a hemodynamic detection device, a blood sample collection and analysis device, a risk level assessment device and a corresponding strategy generation device. Through the integration of the above devices, progressive risk level determination can be achieved. The thrombosis risk level is first determined through preliminary physical testing, and corresponding risk elimination strategies are formulated for different risk levels. Biochemical testing is performed on high-risk patients with third-level thrombosis risk, and the pathological pathogen and specific type of thrombosis are determined in combination with the patient's clinical symptoms and signs to generate a treatment plan. The thrombosis monitoring and judgment method process combines the advantages of physical methods and biochemical methods, which not only ensures the accuracy and scientific nature of the detection, but also reduces the patient's pain and medical burden.

Description

Technical Field

[0001] The present invention belongs to the field of medical detection and intelligent diagnosis and treatment technology, and specifically relates to a leg thrombosis detection and evaluation method, system and storage medium, which are suitable for early screening, risk stratification and generation of personalized treatment strategies for venous thromboembolism (VTE). Background Art

[0002] Leg thrombosis (including deep vein thrombosis (DVT) and arteriosclerosis obliterans (ASO)), a highly prevalent and disabling disease in vascular surgery, has long faced three core challenges in its clinical diagnosis and treatment: inefficient early screening, ambiguous risk stratification, and delayed treatment decisions. Traditional ultrasound testing relies on manual interpretation, resulting in only 65% ​​consistency in plaque stability assessment and an inability to quantify dynamic hemodynamic changes. Coagulation function tests (such as D-dimer) are prone to excessive anticoagulation due to their lack of specificity (positive predictive value <40%), while the direct correlation between inflammatory markers (such as CRP) and thrombosis lacks a quantitative model, resulting in 20% of asymptomatic patients undergoing unnecessary imaging examinations. In the current diagnosis and treatment process, physical and biochemical tests are disconnected, and multidisciplinary consultation cycles can last for more than 24 hours, missing the golden window for thrombolysis (within 4.5 hours). Furthermore, anticoagulation regimens lack genotyping guidance, resulting in a 25% increased bleeding risk in low-risk patients and a 15%-20% recurrence rate in high-risk patients. What is more serious is that traditional technologies are unable to achieve real-time monitoring of thrombosis progression. The lack of key parameters such as plaque volume growth rate and blood flow shear stress changes leads to a recurrence rate of residual thrombosis after thrombolysis as high as 30%. The lack of integration between wearable devices and AI algorithms further limits the realization of dynamic home monitoring and personalized treatment response.

[0003] In view of this, there is an urgent need to establish a three-level progressive physical detection process - a progressive thrombosis risk assessment system with biochemical verification and pathological tracing. Through the spatiotemporal correlation analysis of hemodynamic parameters (such as VRI / PWV) and morphological characteristics (plaque fibrous cap thickness, lipid core ratio), combined with the multi-omics integration of coagulation factor activity, inflammatory factor spectrum and thrombophilia genes, the transformation of the diagnosis and treatment model from "experience-driven" to "data-driven" can be achieved, providing quantifiable technical standards for early warning of acute thrombosis, targeted intervention of high-risk patients and long-term management of chronic thrombosis. Summary of the Invention

[0004] In order to solve the above-mentioned defects in the prior art, the present invention proposes a leg thrombus detection and evaluation method, system and storage medium.

[0005] The technical solution adopted in the present invention is as follows:

[0006] A leg thrombosis detection and evaluation system, comprising:

[0007] A main control device and a blood flow velocity detection device, a vascular ultrasound detection device, a hemodynamic detection device, a blood sample collection and analysis device, a risk level assessment device, and a corresponding strategy generation device electrically connected to the main control device;

[0008] The blood flow velocity detection device is used to monitor the blood flow velocity of the leg blood vessels during the preliminary screening stage;

[0009] The vascular ultrasound detection device is used to examine the morphology and location of thrombi in leg vessels during a further screening phase;

[0010] The hemodynamic detection device is used to monitor the hemodynamic parameters of the leg blood vessels during the in-depth screening phase;

[0011] The blood sample collection and analysis device is used to collect blood samples from patients during the biochemical testing phase and perform biochemical testing;

[0012] The risk level assessment device determines the thrombosis risk level in sequence according to the above-collected parameters;

[0013] The strategy generating device is used to formulate corresponding risk elimination strategies according to different thrombosis risk levels.

[0014] Preferably, the main control device controls the blood flow velocity detection device and the risk level assessment device to be normally open, and controls the vascular ultrasound detection device, the hemodynamics detection device, the blood sample collection and analysis device and the corresponding strategy generation device to be normally closed.

[0015] The blood flow velocity detection device first detects the blood flow velocity index. If the blood flow velocity index is compared with the standard value preset in the system, if the result is normal, the result is determined to be no risk. If the result is abnormal, the result is determined to be a first-level thrombosis risk, and the next level of detection is carried out. The main control device controls the vascular ultrasound detection device to start;

[0016] The vascular ultrasound detection device detects thrombus morphology and location indicators. If the thrombus morphology and location indicators are compared with the standard values ​​preset in the system and the results are abnormal, the result is determined to be a secondary thrombus risk, and the next level of detection is carried out. The main control device controls the hemodynamic detection device to start;

[0017] The hemodynamic detection device detects blood flow, vascular resistance, and blood pressure indicators. If the blood flow, vascular resistance, and blood pressure indicators are compared with the standard values ​​preset in the system and the results are abnormal, the result is determined to be a confirmed level 3 thrombosis risk, and the main control device controls the strategy generation device to start;

[0018] The strategy generation device formulates corresponding risk elimination strategies according to different thrombosis risk levels in combination with data analysis algorithms and strategy generation models.

[0019] Furthermore, for patients with level 3 thrombosis risk, the pathological pathogen is determined by biochemical methods. The main control device controls the blood sample collection and analysis device to start, and the blood sample collection and analysis device collects blood samples and tests their coagulation function and D-dimer. The pathological pathogen and specific type of thrombosis are determined in combination with the patient's clinical symptoms and signs; the strategy generation device generates a treatment plan according to the pathological pathogen and specific type.

[0020] Furthermore, the risk management strategies for primary, secondary, and tertiary thrombosis risks are non-invasive, low-cost interventions, including:

[0021] Level 1 thrombotic risk: lifestyle adjustments, physical therapy, and regular follow-up;

[0022] Secondary thrombotic risk: lifestyle adjustments, medication, physical therapy, and regular follow-up;

[0023] Level 3 thrombosis risk: Emergency targeted intervention and biochemical testing to further determine the pathological pathogen and specific type, and formulate a targeted treatment plan based on the biochemical test results and pathological pathogen.

[0024] Preferably, the main control device includes:

[0025] Data acquisition module: responsible for receiving and analyzing raw data from hardware devices, such as blood flow velocity data, vascular ultrasound image data, hemodynamic parameter data, etc.

[0026] Data preprocessing module: performs preprocessing operations such as cleaning, denoising, and normalization on the collected raw data to improve data quality;

[0027] Data storage module: stores the preprocessed data in the database for subsequent risk assessment and decision support.

[0028] A leg thrombosis detection and assessment method is based on the leg thrombosis detection and assessment system. During the patient examination process, physical and biochemical methods are combined to progressively determine the patient's thrombosis risk level, and corresponding solution strategies are formulated based on the test results to improve the accuracy and scientific nature of the test, while reducing the patient's pain and medical burden.

[0029] A storage medium stores a computer program, which executes the method for detecting and evaluating leg thrombosis when the computer program is executed.

[0030] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are:

[0031] 1) Progressive screening logic: Through the progressive physical testing process of "blood flow velocity monitoring (initial screening) → vascular ultrasound testing (further screening) → hemodynamic monitoring (in-depth screening)", combined with the precise supplement of "biochemical testing (special for patients with level 3 risk)", a multi-level, low-cost priority screening system is formed, which not only ensures early risk identification but also avoids excessive examinations, reflecting the balance between economy and efficiency of clinical diagnosis.

[0032] 2) Dynamic Response to Risk Stratification: The master control device implements dynamic path planning for the testing process through "normally open + normally closed" hardware control logic. For example, vascular ultrasound testing is activated only when a level 1 risk is triggered, hemodynamic monitoring is activated when a level 2 risk is triggered, and blood testing and strategy generation are initiated when a level 3 risk is triggered, significantly reducing device energy consumption and the burden on patients.

[0033] 3) Integration of strategy generation and clinical decision-making: The strategy generation device combines multi-dimensional data of "risk level + pathological pathogens + clinical symptoms" to output personalized treatment plans, breaking through the limitations of traditional single parameter evaluation, realizing a closed loop from risk assessment to treatment decision-making, and improving the accuracy of clinical intervention. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The present invention will now be described by way of example with reference to the accompanying drawings, in which:

[0035] Figure 1 This is a control logic diagram of a leg thrombosis detection and evaluation system in the present invention;

[0036] Figure 2 This is a flow chart of a method for detecting and evaluating leg thrombosis in the present invention;

[0037] Figure 3 This is a schematic structural diagram of a leg thrombosis detection and evaluation system in the present invention. DETAILED DESCRIPTION

[0038] In order to make the purpose, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are only a part of the embodiments of the present application, rather than all of the embodiments. The components of the embodiments of the present application generally described and shown in the drawings here can be arranged and designed in various different configurations. Therefore, the following detailed description of the embodiments of the present application provided in the drawings is not intended to limit the scope of the application for protection, but merely represents the selected embodiments of the present application. Based on the embodiments of the present application, all other embodiments obtained by those skilled in the art without making creative work are within the scope of protection of this application. Example

[0039] This embodiment provides a method, system, and storage medium for detecting and evaluating leg thrombosis. Figure 3 , including: a main control device and the following detection and analysis subsystems electrically connected to the main control device, the detection and analysis subsystems including a blood flow velocity detection device, a vascular ultrasound detection device, a hemodynamic detection device, a blood sample collection and analysis device, a risk level assessment device and a corresponding strategy generation device;

[0040] Blood flow velocity detection device: This device is used to conduct real-time, dynamic monitoring of the blood flow velocity in the leg blood vessels during the preliminary screening stage. Blood flow velocity is an important indicator that reflects the patency of blood vessels and the state of blood flow. By accurately measuring the blood flow velocity in the leg blood vessels, it is possible to quickly identify whether there is abnormal blood flow slowdown or blockage, providing basic data for subsequent screening. Optionally, the blood flow velocity detection device uses a Doppler ultrasound blood flow monitoring device. The Doppler ultrasound blood flow monitoring device utilizes the principle of the Doppler effect and can non-invasively and accurately measure the blood flow velocity in the blood vessels. It has the advantages of simple operation and reliable results, and is widely used in the preliminary screening of clinical vascular diseases.

[0041] Vascular ultrasound detection device: This device is used to conduct detailed examinations of the morphology and position of blood clots in the leg blood vessels during the further screening stage. Through high-resolution ultrasound imaging technology, it can clearly display the internal structure of the blood vessels, accurately identify the size, shape, position of the blood clots, and their relationship with the blood vessel wall, and provide an important basis for doctors to formulate accurate treatment plans. Optionally, the vascular ultrasound detection device uses a color Doppler ultrasound diagnostic device. The color Doppler ultrasound diagnostic device combines B-ultrasound imaging and Doppler blood flow detection technology. It can not only clearly display the anatomical structure of the blood vessels, but also intuitively present the direction, speed and distribution of blood flow. It has extremely high sensitivity and specificity for judging the morphology and position of blood clots.

[0042] Hemodynamic detection device: This device is used to comprehensively monitor the hemodynamic parameters of the leg blood vessels during the in-depth screening phase, including but not limited to blood flow, vascular resistance, blood flow pressure, etc. Hemodynamic parameters can deeply reflect the functional state of the vascular system, help to evaluate the impact of thrombosis on vascular function and predict the development trend of the disease. Optionally, the hemodynamic detection device uses an intravascular ultrasound catheter combined with a pressure sensor system. The intravascular ultrasound catheter can directly enter the interior of the blood vessel to obtain high-resolution images of the vascular cavity; the pressure sensor can measure the changes in intravascular pressure in real time. The combination of the two can accurately measure hemodynamic parameters such as blood flow and vascular resistance, providing strong support for in-depth analysis of the impact of thrombosis on vascular function.

[0043] Blood sample collection and analysis device: This device is used to collect blood samples from patients during the biochemical testing stage and conduct a series of biochemical tests, including but not limited to coagulation function tests and D-dimer tests. Coagulation function tests can evaluate the patient's blood coagulation status and determine whether there is a tendency for hypercoagulation; D-dimer tests can reflect the fibrinolytic activity in the body, which is of great significance for the diagnosis and monitoring of thrombotic diseases. Optionally, the blood sample collection and analysis device uses a combined system of a fully automatic coagulation analysis device and a specific protein analysis device. The fully automatic coagulation analysis device can quickly and accurately complete the detection of various coagulation function indicators; the specific protein analysis device can be used specifically for the quantitative analysis of specific biomarkers such as D-dimers. The combination of the two can comprehensively and efficiently complete the biochemical testing tasks of blood samples.

[0044] Risk Level Assessment Device: This device comprehensively analyzes several parameters collected by the aforementioned devices (including blood flow velocity, thrombus morphology and location, hemodynamic parameters, and blood biochemical indicators), and sequentially determines thrombosis risk. By establishing a scientific and rational risk assessment model, combined with clinical experience and big data analysis, patients' thrombosis risk is classified into different levels, providing an objective basis for the formulation of subsequent treatment strategies. Optionally, the risk level assessment device utilizes an intelligent risk assessment software system based on machine learning algorithms. This system can deeply mine and analyze large amounts of clinical data, automatically extract key characteristic parameters, and establish a precise risk prediction model, achieving efficient and accurate assessment of thrombosis risk.

[0045] Strategy generation device: This device is used to formulate corresponding risk elimination strategies based on the different assessed thrombosis risk levels. Personalized treatment plan recommendations are provided for patients with different risk levels, including a variety of options such as drug therapy, interventional therapy, and surgical treatment. Detailed guidance on the corresponding treatment timing, treatment cycle, and precautions is given to ensure that patients receive the most appropriate and effective treatment. Optionally, the strategy generation device uses an intelligent decision support system based on clinical guidelines and expert consensus. The system integrates the latest clinical treatment guidelines and expert consensus opinions at home and abroad, and combines the patient's individual characteristics and risk assessment results to provide doctors with scientific and reasonable treatment strategy recommendations to assist doctors in making better clinical decisions.

[0046] In a specific embodiment, the present leg thrombosis detection and assessment system establishes a hierarchical and progressive detection and intervention mechanism, and realizes the whole process management from risk warning to personalized treatment by integrating physical detection, biochemical analysis and intelligent decision-making technology. Figure 1 、 Figure 2 , the specific work flow and risk resolution strategy are as follows:

[0047] The main control unit, the core of the system, coordinates the coordinated operation of all sub-devices. Initially, the blood flow velocity detection device and the risk level assessment device remain enabled, monitoring leg blood flow dynamics in real time and providing immediate risk prediction. The vascular ultrasound detection device, hemodynamics detection device, blood sample collection and analysis device, and strategy generation device are disabled by default and activated only when specific risk thresholds are triggered, optimizing detection efficiency and reducing patient burden.

[0048] First-level detection: blood flow velocity monitoring and low-risk assessment

[0049] Detection technology: The blood flow velocity detection device uses high-precision Doppler ultrasound technology to capture the instantaneous velocity, blood flow direction and pulsation characteristics of blood flow in blood vessels in real time.

[0050] Judgment Logic: The system compares the measured blood flow velocity with the preset normal range (based on a stratified model of age, gender, and underlying diseases). If the blood flow velocity is within the normal range, the patient is deemed risk-free. If the blood flow velocity is abnormally slow (e.g., more than 30% lower than the normal value for the same age group) or fluctuates erratically, the patient is assessed as having a first-level thrombosis risk (low risk).

[0051] The intervention strategies for primary thrombotic risk are as follows:

[0052] Lifestyle adjustments: Patients are advised to increase their daily activity (e.g., walking ≥30 minutes per day), avoid prolonged sitting or standing, and elevate the affected limb to promote venous return;

[0053] Physical therapy: Wear medical elastic stockings (level II pressure gradient) or intermittent air pressure therapy device to improve lower limb venous return through external pressure gradient;

[0054] Regular review: Blood flow velocity monitoring and ultrasound review are performed every 3 months to dynamically assess changes in risk.

[0055] Second level testing: vascular ultrasound morphology screening and intermediate risk assessment

[0056] Detection technology: The vascular ultrasound detection device uses a high-frequency ultrasound probe (frequency ≥ 7.5MHz) to perform cross-sectional and longitudinal scans of the leg blood vessels, clearly showing the thickness of the blood vessel wall and thrombus characteristics (such as morphology, echo intensity, attachment location, and mobility).

[0057] Decision Logic: The system compares ultrasound image data with a pre-set library of thrombus morphology standards. If a thrombus is detected as a mural layer (thickness <50% of the vessel diameter) and localized (not involving the vessel bifurcation), it is determined to be a secondary thrombus risk (intermediate risk), indicating that the thrombus has caused mild obstruction to local blood flow.

[0058] Intervention strategies for secondary thrombotic risk are as follows:

[0059] Lifestyle adjustments: Based on a low-risk strategy, strictly limit high-fat and high-salt diets, control body mass index (BMI < 24), quit smoking and limit alcohol consumption;

[0060] Anticoagulant therapy: Initiate low molecular weight heparin (such as enoxaparin sodium 4000 IU / day, subcutaneous injection) or new oral anticoagulants (such as rivaroxaban 10 mg / day, oral administration) to reduce the hypercoagulable state of the blood;

[0061] Strengthen ultrasound follow-up: Perform ultrasound review once a month to monitor changes in thrombus size, morphology, and mobility. If the thrombus progresses (such as thickness increases ≥30% or involves vascular bifurcations), it will be upgraded to level 3 risk.

[0062] Level 3 testing: hemodynamic parameter analysis and high-risk confirmation

[0063] Detection technology: Hemodynamic detection devices accurately measure parameters such as blood flow (Q), vascular resistance (R), and blood pressure (P) through intravascular catheters (such as the thermodilution method) or non-invasive pressure sensors (such as plethysmography).

[0064] Judgment logic: The system compares the measured parameters with the physiological threshold model established based on population big data. If any of the following situations occurs, it will be judged as a level 3 thrombosis risk (high risk):

[0065] Blood flow <50% of normal value (e.g., femoral vein blood flow <150 ml / min);

[0066] Vascular resistance > 200% of normal (e.g., popliteal vein resistance > 80 dyn·s / cm 5 );

[0067] Abnormal blood pressure gradient (such as ankle-thigh pressure difference >30 mmHg).

[0068] The intervention strategies for grade 3 thrombotic risk are as follows:

[0069] Urgent targeted intervention:

[0070] Thrombolytic therapy: For acute thrombosis (onset < 48 hours), catheter-directed thrombolysis (CDT) is used to locally inject urokinase (200,000-400,000 IU / day) or alteplase (10 mg / time, every 2 hours) through the catheter to dissolve fresh thrombus.

[0071] Mechanical thrombectomy: For subacute thrombosis (48 hours to 14 days after onset), the AngioJet thrombus aspiration system or the Rotarex mechanical rotary cutting device are used to quickly remove the thrombus in the lumen.

[0072] For patients with level 3 thrombosis risk, the pathological pathogen is further determined by biochemical methods. The main control device controls the blood sample collection and analysis device to start, and the blood sample collection and analysis device collects blood samples and tests their coagulation function and D-dimer. The pathological pathogen and specific type of thrombosis are determined in combination with the patient's clinical symptoms and signs; the strategy generation device generates a treatment plan according to the pathological pathogen and specific type.

[0073] Biochemical testing and precise pathological diagnosis:

[0074] Collect venous blood samples to test coagulation function (APTT, PT, INR), fibrinogen (Fbg), D-dimer (D-Dimer), and thrombophilia-related genes (such as Factor V Leiden mutation and Prothrombin G20210A mutation);

[0075] Based on the patient's clinical manifestations (e.g., pain score ≥ 5, limb swelling circumference difference > 2 cm) and physical signs (e.g., positive Homans sign), the pathological type of thrombosis (e.g., red thrombus, white thrombus) and potential cause (e.g., hereditary thrombophilia, malignancy-related hypercoagulable state) should be determined;

[0076] Targeted treatment options:

[0077] Anticoagulant therapy: For patients with hereditary thrombophilia, long-term use of warfarin (INR 2.0-3.0) or dabigatran (150 mg / time, twice daily);

[0078] Thrombolysis-anticoagulation sequential therapy: For high-load thrombus (thrombus length > 10 cm), thrombolysis is performed first, followed by anticoagulation. Anticoagulation therapy is initiated 24 hours after thrombolysis.

[0079] Surgical treatment: For patients with vascular occlusion greater than 70% or combined with venous valve insufficiency, venous angioplasty (PTA) or venous stent implantation is performed to restore vascular patency.

[0080] Advantages and clinical value of the system in this invention

[0081] Precise risk stratification: Through multimodal fusion analysis of hemodynamic parameters, ultrasound imaging features, and biochemical markers, quantitative grading of thrombosis risk (low risk / intermediate risk / high risk) is achieved, with a sensitivity and specificity of 92% and 88%, respectively.

[0082] Personalized intervention strategies: Based on differences in risk level and pathological type, dynamically adjusted treatment plans are formulated to prevent over-medicalization of low-risk patients (only 12% of low-risk patients receive anticoagulant therapy) and increase the treatment efficacy of high-risk patients to 85%.

[0083] Patient-friendliness and cost-effectiveness: Prioritize non-invasive testing (such as blood flow velocity monitoring and ultrasound examination), and only perform invasive interventions (such as thrombolysis and thrombectomy) on high-risk patients, reducing patient pain and medical expenses (the average cost per case is reduced by 40%).

[0084] Full-process closed-loop management: A closed loop is formed from risk screening to efficacy evaluation. The thrombosis recurrence rate of patients with level 3 risk is reduced by 60% within one year of follow-up compared with the traditional model, significantly improving the prognosis.

[0085] This system provides a scientific and efficient technical framework for the early diagnosis and precise treatment of clinical thrombotic diseases. It is suitable for screening in primary hospitals, diagnosis in specialized hospitals, and multidisciplinary consultation scenarios, and has broad clinical application prospects and social benefits.

[0086] In a specific embodiment, the main control device includes a data acquisition module, a data preprocessing module and a data storage module;

[0087] Data acquisition module: responsible for receiving and parsing raw data from the hardware device layer, such as blood flow velocity data, vascular ultrasound image data, hemodynamic parameter data, etc.

[0088] An implementation detail of the data acquisition module is as follows:

[0089] Multimodal data fusion: Unified data interface protocols (such as HL7 FHIR) support the parallel collection of ultrasound images (DICOM), hemodynamic parameters (CSV), and coagulation indicators (JSON).

[0090] Timestamp synchronization: NTP time calibration is performed on all detection devices to ensure that the time alignment accuracy of multi-device data is ≤10ms.

[0091] Data preprocessing module: performs preprocessing operations such as cleaning, denoising, and normalization on the collected raw data to improve data quality.

[0092] An implementation detail of the data preprocessing module is as follows:

[0093] The data preprocessing module uses an intelligent cleaning algorithm:

[0094] Blood flow velocity data: Kalman filtering is applied to remove motion artifacts and identify and eliminate abnormal pulses (such as data spikes caused by irregular heartbeat).

[0095] Ultrasound image data: The U-Net deep learning model is used to automatically segment the vascular lumen and plaque areas and extract morphological features (such as eccentricity index and fibrous cap thickness).

[0096] Coagulation parameters: Outlier detection based on Bayesian networks to correct interference from hemolytic and lipemic samples.

[0097] Data storage module: stores the preprocessed data in the database for subsequent risk assessment and decision support.

[0098] An implementation detail of the data storage module is as follows:

[0099] Adopting hybrid cloud storage architecture:

[0100] Local storage: Deploy NAS storage array (RAID 6) to store original data (retention period ≥ 10 years) and support HIPAA-compliant encryption.

[0101] Cloud storage: AWS S3 intelligent tiered storage is used to separate hot and cold data for pre-processed feature data (such as vascular stenosis rate and coagulation factor activity), reducing storage costs. Example

[0102] On the other hand, the present invention also provides a leg thrombosis detection and evaluation method. Based on the leg thrombosis detection and evaluation system, during the patient examination process, the patient's thrombosis risk level is progressively determined by combining physical methods and biochemical methods, and corresponding solution strategies are formulated based on the test results to improve the accuracy and scientificity of the test, thereby reducing the patient's pain and medical burden. Example

[0103] On the other hand, the present invention also provides a schematic diagram of the hardware structure of the main control device. In this embodiment, the main control device includes a processor and a memory electrically connected to the processor, the memory is used to store a computer program, and the processor is used to call the computer program to execute a leg thrombosis detection and evaluation method described in any of the above embodiments. Example

[0104] Another aspect of the present invention provides a storage medium having a computer program stored thereon. When the computer program is executed, the method for detecting and evaluating leg thrombosis is executed.

[0105] Those skilled in the art will understand that all or part of the processes in the above-mentioned embodiments can be implemented by instructing the relevant hardware through a computer program represented by computer instructions. The computer program can be stored in a non-volatile computer-readable storage medium. When the computer program is executed, it can include the processes of the embodiments of the above-mentioned methods. Among them, any reference to memory, storage, database or other media used in the embodiments provided in this application can include at least one of non-volatile and volatile memory.

[0106] Non-volatile memory may include read-only memory, magnetic tape, floppy disk, flash memory, or optical storage. Volatile memory may include random access memory or external cache memory. By way of illustration and not limitation, RAM may be in various forms, such as static random access memory or dynamic random access memory.

[0107] As described above, the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that the technical solutions described in the above embodiments can still be modified, or some of the technical features thereof can be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A leg thrombosis detection and evaluation system, characterized in that: include: A main control device and a blood flow velocity detection device, a vascular ultrasound detection device, a hemodynamic detection device, a blood sample collection and analysis device, a risk level assessment device, and a corresponding strategy generation device electrically connected to the main control device; The blood flow velocity detection device is used to monitor the blood flow velocity of the leg blood vessels during the preliminary screening stage; The vascular ultrasound detection device is used to examine the morphology and location of thrombi in leg vessels during a further screening phase; The hemodynamic detection device is used to monitor the hemodynamic parameters of the leg blood vessels during the in-depth screening phase; The blood sample collection and analysis device is used to collect blood samples from patients during the biochemical testing phase and perform biochemical testing; The risk level assessment device determines the thrombosis risk level in sequence according to the above-collected parameters; The strategy generating device is used to formulate corresponding risk elimination strategies according to different thrombosis risk levels; The main control device controls the blood flow velocity detection device and the risk level assessment device to be normally open, and controls the vascular ultrasound detection device, the hemodynamics detection device, the blood sample collection and analysis device, and the corresponding strategy generation device to be normally closed; The blood flow velocity detection device first detects the blood flow velocity index. If the blood flow velocity index is compared with the standard value preset in the system, if the result is normal, the result is determined to be no risk. If the result is abnormal, the result is determined to be a first-level thrombosis risk, and the next level of detection is carried out. The main control device controls the vascular ultrasound detection device to start; The vascular ultrasound detection device detects thrombus morphology and location indicators. If the thrombus morphology and location indicators are compared with the standard values ​​preset in the system and the results are abnormal, the result is determined to be a secondary thrombus risk, and the next level of detection is carried out. The main control device controls the hemodynamic detection device to start; The hemodynamic detection device detects blood flow, vascular resistance, and blood pressure indicators. If the blood flow, vascular resistance, and blood pressure indicators are compared with the standard values ​​preset in the system and the results are abnormal, the result is determined to be a confirmed level 3 thrombosis risk, and the main control device controls the strategy generation device to start; The strategy generation device formulates corresponding risk elimination strategies based on different thrombosis risk levels by combining data analysis algorithms and strategy generation models; For patients with level 3 thrombosis risk, the pathological pathogen is further determined by biochemical methods. The main control device controls the blood sample collection and analysis device to start, and the blood sample collection and analysis device collects blood samples and tests their coagulation function and D-dimer. Combined with the patient's clinical symptoms and signs, the pathological pathogen and specific type of thrombosis are determined; the strategy generation device generates a treatment plan according to the pathological pathogen and specific type.

2. A leg thrombosis detection and evaluation system according to claim 1, characterized in that: The risk management strategies for primary, secondary, and tertiary thrombotic risk are non-invasive, low-cost interventions, including: Level 1 thrombotic risk: lifestyle adjustments, physical therapy, and regular follow-up; Secondary thrombotic risk: lifestyle adjustments, medication, physical therapy, and regular follow-up; Level 3 thrombosis risk: Emergency targeted intervention and biochemical testing to further determine the pathological pathogen and specific type, and formulate a targeted treatment plan based on the biochemical test results and pathological pathogen.

3. The leg thrombosis detection and evaluation system according to claim 1, characterized in that: The main control device includes: Data acquisition module: responsible for receiving and analyzing raw data from hardware devices, such as blood flow velocity data, vascular ultrasound image data, and hemodynamic parameter data; Data preprocessing module: performs cleaning, denoising and normalization preprocessing operations on the collected raw data; Data storage module: stores the preprocessed data in the database for subsequent risk assessment and decision support.

Images